We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Read MoreHide Full Article
Agenus Inc. (AGEN - Free Report) reported second-quarter 2019 loss of 38 cents per share, wider than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago quarter’s loss of 24 cents.
The company generated revenues of $15.7 million, including non-cash royalties, down from $15.9 million in the year-ago quarter. Revenues beat the Zacks Consensus Estimate of $5 million.
Shares of the company have rallied 7.6% year to date against the industry’s decline of 0.5%.
Quarterly Highlights
Research and development expenses surged 54.6% to $45.2 million. General and administrative expenses decreased 1% to $11.9 million.
Pipeline Update
Agenus is a clinical-stage, immuno-oncology company with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms.
In December 2018, the company inked a collaboration deal with Gilead Sciences Inc. (GILD - Free Report) to develop and commercialize up to five immuno-oncology (I-O) therapies. Agenus received $150 million in upfront cash payment and equity investment and is eligible to receive approximately $1.7 billion in future fees and milestones. In January 2019, it announced the closing of its deal with Gilead.
In August 2019, Agenus received $7.5 million in cash as a milestone payment from Gilead, after the FDA accepted the former's investigational new drug (IND) application for AGEN2373. AGEN1423 is an investigational agent designed to mitigate the toxicity observed with competitor molecules. This molecule has great potential in patients with cancer.
GlaxoSmithKline plc’s (GSK - Free Report) herpes zoster vaccine, Shingrix, which contains Agenus' proprietary immune adjuvant QS-21 Stimulon achieved over $1 billion in revenues in its first year of launch. It remains on track to reach $1.3 billion in revenues in 2019.
Acorda’s loss per share estimates have narrowed from $3.59 to $2.74 for 2019 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, the average being 69.68%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Agenus Inc. (AGEN - Free Report) reported second-quarter 2019 loss of 38 cents per share, wider than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago quarter’s loss of 24 cents.
The company generated revenues of $15.7 million, including non-cash royalties, down from $15.9 million in the year-ago quarter. Revenues beat the Zacks Consensus Estimate of $5 million.
Shares of the company have rallied 7.6% year to date against the industry’s decline of 0.5%.
Quarterly Highlights
Research and development expenses surged 54.6% to $45.2 million. General and administrative expenses decreased 1% to $11.9 million.
Pipeline Update
Agenus is a clinical-stage, immuno-oncology company with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms.
In December 2018, the company inked a collaboration deal with Gilead Sciences Inc. (GILD - Free Report) to develop and commercialize up to five immuno-oncology (I-O) therapies. Agenus received $150 million in upfront cash payment and equity investment and is eligible to receive approximately $1.7 billion in future fees and milestones. In January 2019, it announced the closing of its deal with Gilead.
In August 2019, Agenus received $7.5 million in cash as a milestone payment from Gilead, after the FDA accepted the former's investigational new drug (IND) application for AGEN2373. AGEN1423 is an investigational agent designed to mitigate the toxicity observed with competitor molecules. This molecule has great potential in patients with cancer.
GlaxoSmithKline plc’s (GSK - Free Report) herpes zoster vaccine, Shingrix, which contains Agenus' proprietary immune adjuvant QS-21 Stimulon achieved over $1 billion in revenues in its first year of launch. It remains on track to reach $1.3 billion in revenues in 2019.
Agenus Inc. Price, Consensus and EPS Surprise
Agenus Inc. price-consensus-eps-surprise-chart | Agenus Inc. Quote
Zacks Rank & Stock to Consider
Agenus currently carries a Zacks Rank #3 (Hold).
A better-ranked stock is Acorda Therapeutics Inc. carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Acorda’s loss per share estimates have narrowed from $3.59 to $2.74 for 2019 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, the average being 69.68%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>